Head-To-Head Survey: MDxHealth (MDXH) and Its Peers
Head-To-Head Survey: MDxHealth (MDXH) and Its Peers
MDxHealth (NASDAQ:MDXH – Get Rating) is one of 45 publicly-traded companies in the "Medical laboratories" industry, but how does it contrast to its rivals? We will compare MDxHealth to similar companies based on the strength of its valuation, institutional ownership, dividends, profitability, risk, earnings and analyst recommendations.
MDxHealth（NASDAQ：MDXH — 獲得評級）是「醫療實驗室」行業中 45 家上市公司之一，但它與競爭對手有什麼對比？我們將根據其估值，機構所有權，股息，盈利能力，風險，收益和分析師建議的實力將 MDxHealth 與同類公司進行比較。
Earnings and Valuation
收益及估值
This table compares MDxHealth and its rivals gross revenue, earnings per share and valuation.
此表格比較了 MDxHealth 及其競爭對手的總收入，每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MDxHealth | $37.05 million | -$44.04 million | -1.37 |
| MDxHealth Competitors | $964.07 million | -$107.46 million | 4.34 |
| 總收入 | 淨收入 | 市盈比率 | |
| MDX 健康 | 三千五百萬美元 | -4.04 億元 | -1.37 |
| MDX 健康競爭對手 | 九億四百零七萬 | -10746 萬美元 | 4.34 |
MDxHealth's rivals have higher revenue, but lower earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
MDX 健康的競爭對手擁有更高的收入，但收入低於 MDX 健康。MDxHealth 的交易價格與收益比率低於競爭對手，這表明它目前比其他行業中的公司更經濟實惠。
Institutional & Insider Ownership
機構和內幕所有權
12.6% of MDxHealth shares are held by institutional investors. Comparatively, 47.0% of shares of all "Medical laboratories" companies are held by institutional investors. 16.4% of shares of all "Medical laboratories" companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
12.6% 的股份由機構投資者持有。相比之下，所有「醫學實驗室」公司股份的 47.0％ 由機構投資者持有。所有「醫學實驗室」公司的 16.4％ 股份由公司內部人員持有。強大的機構所有權表明捐贈，對沖基金和大型資金經理認為股票有望實現長期增長。
Analyst Ratings
分析師評級
This is a summary of recent ratings for MDxHealth and its rivals, as provided by MarketBeat.
這是 MdxHealth 及其競爭對手的最近評分的摘要，由 MarketBeat 提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 0 | 0 | 3 | 0 | 3.00 |
| MDxHealth Competitors | 167 | 826 | 1723 | 32 | 2.59 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| MDX 健康 | 0 | 0 | 3 | 0 | 3.00 |
| MDX 健康競爭對手 | 167 | 826 | 1723 | 32 | 2.59 |
MDxHealth currently has a consensus target price of $12.00, indicating a potential upside of 359.77%. As a group, "Medical laboratories" companies have a potential upside of 53.00%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than its rivals.
MDX 健康目前的共識目標價為 12.00 美元，表明潛在的上行空間為 359.77％。作為一個集團，「醫學實驗室」公司的潛在上升空間為 53.0％。鑑於 MDxHealth 的更強大的共識評級和更高的可能上行空間，分析師清楚地認為 MDxHealth 比競爭對手更有利。
Risk & Volatility
風險及波動性
MDxHealth has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, MDxHealth's rivals have a beta of 1.00, indicating that their average share price is 0% more volatile than the S&P 500.
MDX 健康的測試版為 0.29，表明其股價比標普 500 低了 71％ 的波動性。相比之下，MDxHealth 的競爭對手的測試版為 1.00，這表明他們的平均股價比標普 500 的波動性高 0％。
Profitability
盈利
This table compares MDxHealth and its rivals' net margins, return on equity and return on assets.
此表格比較 MDxHealth 及其競爭對手的淨利潤率、權益回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -118.86% | -218.20% | -44.01% |
| MDxHealth Competitors | -1,181.51% | -78.19% | -28.91% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| MDX 健康 | -118.86% | -218.20% | -44.01% |
| MDX 健康競爭對手 | -1,181.51% | -78.19% | -28.91% |
Summary
摘要
MDxHealth rivals beat MDxHealth on 8 of the 13 factors compared.
MDX 健康競爭對手在 8 個因素中的 13 個因素中擊敗了 MDX 健康。
About MDxHealth
關於中心健康
(Get Rating)
(取得評分)
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MdxHealth SA 是一家商業階段的精密診斷公司，在美國，荷蘭，比利時，西班牙，波蘭，意大利，歐盟其他地區以及國際上提供泌尿外科解決方案。其新穎的前列腺癌基因組 test 解決方案是 SelectMDX，一種非侵入性尿液 test；以及表觀遺傳測試 ConmiMMDX，它為醫生提供臨床途徑，以識別臨床前列腺癌，同時最大限度地減少使用容易出現併發症的侵入性手術。該公司以前被稱為商業科學 SA，並在 2010 年 10 月更名為 MDX 健康有限公司。萬德健康有限公司成立於 2003 年，總部位於比利時赫斯塔爾。
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 MDX 健康日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 MDxHealth 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。